World Pharmaceutical Contract Sales Market 2013-2023

November 2012 | 160 pages | ID: WC3A37B969EEN
Visiongain

Abstracts

How to find pharma contract sales trends and revenue predictions - new study

Where are pharma contract sales organisations (CSOs) heading? Visiongain's updated report gives you forecasted revenues to 2023 for that market and shows you trends, opportunities and industry prospects.

For sales outsourcing our study lets you assess projected sales data at overall world market, submarket and national level. There you investigate the most lucrative areas in that industry and market. Segments hold great potential, as do service providers.

Forecasts and other analyses to help you stay ahead in knowledge

In our study you find revenue forecasting to 2023, growth rates and market shares. Also, you examine qualitative analysis (SWOT and STEP), company profiles, technologies and regulatory policy. You receive 59 tables, 53 charts and a research interview.

There is rising demand for CSO services. Now you can stay ahead in knowledge, benefiting your research and analyses.

The following sections show what you discover in our report.

You see prospects for the world market and submarkets

In addition to analyses of the overall world market, you see revenue forecasting of world-level submarkets to 2023:

• Personal promotion of pharmaceuticals
• Non-personal promotion of drugs (also with the components teledetailing and edetailing forecasted)
• Medical education
• Other contract services.

Our investigation shows business research and analysis with individual sales predictions and discussions. You see competition, as well as commercial drivers and restraints.

The work also breaks the overall world forecast into leading national markets.

What are the prospects in leading regions and countries?

Developments worldwide will influence the market to 2023, especially demand in emerging countries. There are many opportunities worldwide. CSOs and pharma clients will benefit.

You discover individual revenue forecasts to 2023 for eleven national markets:

• US
• Japan
• Germany, France, UK, Italy and Spain (EU5), with a forecast for Europe too
• Brazil, Russia, India and China (BRIC nations).

Our analyses show there will be high revenue growth in established pharma markets, but the fastest growth will occur in BRIC countries. You see events influencing future results.

What issues affect pharma sales outsourcing?

Our study discusses many issues affecting the sector from 2012 onwards:

• Overcoming of limited access to doctors and other healthcare professionals
• Dedicated and syndicated sales representatives
• Recruitment and training of teams
• Moves away from the traditional contract sales model
• Multichannel and closed loop marketing
• Specialty pharmaceutical reps for complex drugs (e.g. biologics and biosimilars).

Also, you find coverage of these aspects:

• Detailing, sampling and customer relationship management (CRM)
• Market demand and adding services (e.g. consultancy) for organisations' needs
• New media - technology aiding medical selling, promotion and education
• Regulations, policies and promotional codes
• Medical science liaison (MSL).

You see discussions of social, technological, economic and political matters, finding out what stimulates and restrains the industry. Discover what the future holds.

Leading companies and market value in 2013

What will happen next? Overall world revenue for that market area will reach $3,912m in 2013, our report forecasts. We predict strong revenue growth from 2012 to 2023.

In our study you find discussions of Quintiles, inVentiv Health, United Drug, PDI and other companies. Discover outlooks of leading CSOs in the US, Asia Pacific and Europe. This decade, many opportunities will arise for service providers and clients.

Eight ways World Pharmaceutical Contract Sales Market 2013-2023 benefits you

To sum up, our report gives you the following information on the topic:

• Forecasted revenues to 2023 for the overall world market and 6 submarkets - find the industry's prospects
• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see leading national and regional prospects
• Profiles of 12 leading companies - find services, results, strategies and outlooks
• Opinions on the sector - discover views, including a research interview
• Coverage of market access and rising power of healthcare payers
• Investigation of competition and opportunities influencing sales
• Discussions of what stimulates and restrains the industry and market
• Prospects for established companies and firms seeking entry.

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative and revenue growth is likely.

With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research, analyses and decisions, saving you time too.

You discover prospects for pharma sales services by ordering now

Visiongain's study is for everyone needing analysis of the industry and market for contract pharmaceutical sales. You find data, trends and predictions. Please order our report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Pharma Contract Sales: World Market Review
1.2 Report Contents
1.3 Research and Analysis Methods

2. INTRODUCTION TO PHARMACEUTICAL CONTRACT SALES

2.1 Introduction to Pharmaceutical Sales
  2.1.1 The Need for Pharmaceutical Sales
  2.1.2 Common Sales Models
  2.1.3 Detailing
    2.1.3.1 Sampling
  2.1.4 Direct-to-Consumer (DTC) Marketing
2.2 Changes to Pharmaceutical Sales
  2.2.1 Patent Expiries
  2.2.2 Sales Staff Reductions
  2.2.3 Limited Access to Doctors
2.3 Pharmaceutical Contract Sales
  2.3.1 Pharmaceutical Outsourcing
    2.3.1.1 Benefits and Weaknesses of Outsourcing Pharmaceutical Sales
  2.3.2 Contract Sales Organisations (CSOs)
  2.3.3 Services Offered by CSOs
    2.3.3.1 Dedicated and Syndicated Sales Teams
    2.3.3.2 Non-Personal Promotion
    2.3.3.3 Medical Education Services: Advising Doctors and Nurses
    2.3.3.4 Recruitment and Training

3. THE PHARMACEUTICAL CONTRACT SALES MARKET 2013-2023

3.1 The Pharmaceutical Contract Sales Market in 2011-2012
  3.1.1 What Are the Leading Sectors of the Contract Sales Market in 2011 and 2012?
  3.1.2 Revenue Fluctuation for Leading CSOs 2009-2012
3.2 The Pharmaceutical Contract Sales Organisation Market: Overall Revenue Forecast 2013-2023
  3.2.1 What Will Drive and Restrain Growth in the Contract Sales Market Between 2013 and 2023?
  3.2.2 Comparison of Contract Sales Submarket Shares 2013-2023
3.3 Contract Personal Promotion Services Submarket 2013-2023
  3.3.1 Contract Personal Promotion Services Submarket: Revenue Forecast, 2013-2023
  3.3.2 Factors Affecting Demand for Contract Personal Promotion Services 2013-2023
3.4 Contract Non-Personal Promotion Services Submarket 2013-2023
  3.4.1 Contract Non-Personal Promotion Services Submarket: Revenue Forecast 2013-2023
  3.4.2 New Media to Drive Sector Growth 2013-2023
  3.4.3 Contract Teledetailing Services Submarket: Revenue Forecast 2013-2023
  3.4.4 Strong Revenue Growth for the Contract eDetailing Services Submarket 2013-2023
3.5 Medical Education Services Submarket 2013-2023
  3.5.1 The Role of Education Services in the Pharmaceutical Industry
    3.5.1.1 Medical Science Liaison (MSL)
    3.5.1.2 Clinical Education
  3.5.2 Contract Medical Education Services Submarket: Revenue Forecast 2013-2023
  3.5.3 Submarket Drivers and Restraints 2013-2023

4. LEADING NATIONAL MARKETS FOR PHARMACEUTICAL CONTRACT SALES 2013-2023

4.1 Breakdown of the Global Pharmaceutical Contract Sales Market 2011-2012
  4.1.1 Comparison of Pharmaceutical Sales Models in Developed Markets
4.2 Leading National Markets: Revenue Forecasts 2013-2023
4.3 The US: The Leading Global Contract Sales Market 2013-2023
4.4 The Outlook for Pharmaceutical Contract Sales in Europe 2013-2023
  4.4.1 Leading European Markets: Revenue Forecasts 2013-2023
  4.4.2 The UK: The Leading European Contract Sales Market 2013-2023
    4.4.2.1 The Impact of the Health and Social Care Act 2012 on Contract Sales in the UK
  4.4.3 Germany: Revenue Forecast 2013-2023
    4.4.3.1 AMNOG: Restraining Growth in the German Contract Sales Market
  4.4.4 France: Revenue Growth 2013-2023
  4.4.5 Italy: Revenue Forecast 2013-2023
  4.4.6 Spain: The Impact of Increased Generic Prescribing 2013-2023
4.5 Japan: The Entry of Global CSOs and Revenue Growth 2013-2023
4.6 What Does the Future Hold for Contract Sales in Emerging Markets?
  4.6.1 Brazil: Revenue Forecast 2013-2023
  4.6.2 Russia: Revenues 2013-2023
    4.6.2.1 Akrikhin: A Russian CSO
  4.6.3 India: Revenues 2013-2023
    4.6.3.1 Industry Bodies in the Indian Pharmaceutical Sales Market
  4.6.4 China: Future Revenues for the Leading Emerging Contract Sales Market 2013-2023

5. LEADING PHARMACEUTICAL CONTRACT SALES ORGANISATIONS 2012

5.1 Comparing World Market Shares for Global and National CSOs 2011
5.2 inVentiv Health
  5.2.1 inVentiv Health Wins Contracts in Diabetes and Other Indications 2011-2012
  5.2.2 Financial Performance 2010-2011: A Global Market Leader
  5.2.3 inVentiv's Rapid Expansion in the Asian Market
  5.2.4 How Can inVentiv Health Maintain its Market Leader Status?
5.3 Quintiles
  5.3.1 Contract Sales Services for Drugs and Medical Devices 2012
  5.3.2 Which Emerging Markets is Quintiles Entering?
  5.3.3 eDetailing and Market Access for the US
  5.3.4 Strategic Partnerships for Future Growth
5.4 United Drug
  5.4.1 Expanding Through Acquisitions
  5.4.2 United Drug Acquires Pharmexx, a Leading European Competitor
    5.4.2.1 Pharmexx: Varied Financial Performance 2009-2011
  5.4.3 United Drug: Above-Market Revenue Growth 2008-2011
  5.4.4 More Acquisitions for Future Growth?
5.5 CSOs in the US Market 2012
  5.5.1 OnCall
  5.5.2 PDI
    5.5.2.1 Adding Services to Meet Market Demands 2011
    5.5.2.2 Interpace BioPharma: Aiding New Drug Launches
    5.5.2.3 More Than $100m in Contracts Awarded 2012
    5.5.2.4 Financial Performance 2009-2012
    5.5.2.5 PDI: Outlook 2013-2023
  5.5.3 Publicis Touchpoint Solutions
    5.5.3.1 New Model for Sales Rep Recruitment and Other Additional Services 2011
5.6 CSOs for Market Entry in Asia Pacific
  5.6.1 CMIC
    5.6.1.1 Recent Financial Performance
  5.6.2 Invida: Moving Away from the Traditional Contract Sales Model
  5.6.3 Zuellig Pharma
5.7 CSOs Targeting National Markets in Europe
  5.7.1 Marvecs
  5.7.2 Sofip: Three Decades of Experience in France
  5.7.3 Merqurio: Field Sales and New Media Detailing Services in Italy

6. PHARMACEUTICAL CONTRACT SALES: INDUSTRY TRENDS 2013-2023

6.1 Pharmaceutical Contract Sales Market: Strengths and Weaknesses 2012
  6.1.1 There Are Benefits and Risks to Outsourcing Pharmaceutical Sales
6.2 Pharmaceutical Contract Sales Market: Opportunities and Threats 2013-2023
  6.2.1 Internal and Outsourced Sales Reps: Facing Similar Opportunities and Challenges
  6.2.2 Pharmaceutical Contract Sales Market: STEP Analysis 2013-2023
6.3 Social Factors
  6.3.1 Sales Reps and Overtime in the US
  6.3.2 Ethics Play an Important Role in Pharmaceutical Sales
  6.3.3 Access to Doctors is Declining
    6.3.3.1 Akcess: A Novel Model for Arranging Meetings
6.4 Technology as a Growth Driver 2013-2023
  6.4.1 Using Smartphones and Tablet PCs to Improve Detailing
    6.4.1.1 The iPad: Popular in the Pharmaceutical Industry
  6.4.2 How Can Social Media Help Pharmaceutical Sales?
    6.4.2.1 There Are Benefits to Outsourcing Social Media Campaigns
    6.4.2.2 Case Study: DottNet.it - Italy's First Social Network for Doctors
  6.4.3 The Rise of eDetailing
  6.4.4 Cloud Computing Can be Useful for Pharmaceutical Sales
6.5 The Role of Economic Pressures in Contract Sales
  6.5.1 Pharmaceutical Companies Are Cutting In-House Sales Staff
6.6 Political Factors and CSOs
  6.6.1 New Influential Stakeholders in Pharmaceutical Sales
6.7 The Needs of Pharmaceutical Clients Are Changing
  6.7.1 Developing and Marketing Drugs for Orphan Diseases
  6.7.2 The Threat of Generics and Opportunity of Biosimilars
  6.7.3 Targeting Drug Launches in Emerging Asian Markets
6.8 What Differences Will There be in Future Sales Strategies?
  6.8.1 CSOs Adapting to the New Sales Model
  6.8.2 Customer Relationship Management (CRM)
    6.8.2.1 How Can iPads Help with CRM?
    6.8.2.2 Case Study: Veeva Systems
  6.8.3 Closed Loop Marketing (CLM)
  6.8.4 Personal Promotion: The Future
  6.8.5 Using Multichannel Marketing for Better Coverage
    6.8.5.1 The Outsourcing Advantage for Multichannel Marketing
  6.8.6 Specialty Pharmaceutical Reps Required for Complex Drug Marketing
    6.8.6.1 Complex Drugs and Patient Compliance
    6.8.6.2 Corcept Therapeutics: An Example of Specialty Drug Marketing
    6.8.6.3 Outsourcing Specialty Rep Recruitment and Management
  6.8.7 Key Account Management
6.9 Market Access
  6.9.1 Market Access is Becoming More Challenging
  6.9.2 Market Access Planning Must Begin Early
  6.9.3 What Can CSOs Offer to Improve Market Access Success?
6.10 Outlook for Pharmaceutical Sales Outsourcing 2013-2023
  6.10.1 Consolidation in the Contract Sales Market
  6.10.2 Strategic Partnering: An Attractive Model for CSOs

7. REGULATORY ASPECTS TO PHARMACEUTICAL SALES IN 2012

7.1 Pharmaceutical Sales Regulation in the US
  7.1.1 Physician Payment Sunshine Act: Increasing Transparency
  7.1.2 The PhRMA Marketing Code
  7.1.3 US Overtime Rules
7.2 Regulatory Developments in Pharmaceutical Sales in the EU
  7.2.1 EFPIA and Pharmaceutical Sales
  7.2.2 Direct-to-Consumer (DTC) Advertising in the EU
  7.2.3 Regulatory Developments in France in 2011-2012
  7.2.4 Germany: Pharmaceutical Sales Reps and Gifts
  7.2.5 The UK Bribery Act 2010: Increased Focus on Interactions with Doctors
7.3 Pharmaceutical Sales Regulations in Japan Are Similar to the US and EU
  7.3.1 The JPMA Promotion Code
7.4 Emerging Markets Aligning Regulations with Developed Markets
  7.4.1 Brazil: Increased Clarity in Drug Advertising Rules
  7.4.2 Changes to Detailing Rules in Russia 2011
  7.4.3 Gifts and Payments in India
  7.4.4 China: Strict Bribery Rules Introduced 2010

8. RESEARCH INTERVIEW

8.1 Chris Anderson, Managing Director, Evolve Selection
  8.1.1 Evolve Selection
  8.1.2 There Are Benefits to Using CSOs for Market Access
    8.1.2.1 Changing Demand for Market Access Services
  8.1.3 Market Access in the UK
  8.1.4 Sales Reps: Demand for New Skills

9. CONCLUSIONS OF OUR STUDY

9.1 What Are the Key Elements of the Contract Sales Market in 2012?
9.2 What Will Drive Growth in the Contract Sales Market from 2013 to 2023?
  9.2.1 Contract Sales in Developed Markets 2013-2023
  9.2.2 Contract Sales in Emerging Markets 2013-2023
9.3 Changing Demands from the Pharmaceutical Industry

List Of Tables

LIST OF TABLES

Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Patent Expiries: Revenue at Risk for Big Pharma, 2012-2015
Table 3.1 Pharmaceutical Contract Sales Market, 2009-2011
Table 3.2 Pharmaceutical Contract Sales Market by Sector, 2011
Table 3.3 PDI: Sales Reps Employed, 2005-2011
Table 3.4 Pharmaceutical Contract Sales Market: Overall Market and Revenue Forecasts by Sector, 2011-2023
Table 3.5 Pharmaceutical Contract Sales Market: Drivers and Restraints, 2013-2023
Table 3.6 Pharmaceutical Contract Sales Submarket Shares, 2011-2023
Table 3.7 Personal Promotion Services Submarket: Revenue Forecast, 2011-2023
Table 3.8 Personal Promotion Services Submarket: Drivers and Restraints, 2013-2023
Table 3.9 Non-Personal Promotion Services Submarket by Sector, 2011
Table 3.10 Non-Personal Promotion Services Submarket: Overall Submarket and Revenue Forecasts by Sector, 2011-2023
Table 3.11 Non-Personal Promotion Services: Submarket Shares, 2011-2023
Table 3.12 Non-Personal Promotion Services Submarket: Drivers and Restraints, 2013-2023
Table 3.13 Teledetailing Services Submarket: Revenue Forecast, 2011-2023
Table 3.14 eDetailing Services Submarket: Revenue Forecast, 2011-2023
Table 3.15 Medical Education Services Submarket: Revenue Forecast, 2011-2023
Table 3.16 Medical Education Services Submarket: Drivers and Restraints, 2013-2023
Table 4.1 Pharmaceutical Contract Sales Market by Country, 2011
Table 4.2 Proportion of Sales Reps Outsourced in Developed Markets, 2012
Table 4.3 Pharmaceutical Contract Sales Market: Revenue Forecasts by Country, 2011-2023
Table 4.4 Pharmaceutical Contract Sales: Market Shares by Country, 2011-2023
Table 4.5 US Contract Sales Submarket: Revenue, 1995-2011
Table 4.6 US Submarket: Revenue Forecast, 2011-2023
Table 4.7 Pharmaceutical Contract Sales: European Market by Leading Country, 2011
Table 4.8 European Pharmaceutical Contract Sales Market: Revenue Forecasts by Leading Country 2011-2023
Table 4.9 UK Submarket: Revenue Forecast, 2011-2023
Table 4.10 German Submarket: Revenue Forecast, 2011-2023
Table 4.11 French Submarket: Revenue Forecast, 2011-2023
Table 4.12 Italian Submarket: Revenue Forecast, 2011-2023
Table 4.13 Spanish Submarket: Revenue Forecast, 2011-2023
Table 4.14 Japanese Submarket: Revenue Forecast, 2011-2023
Table 4.15 Brazilian Submarket: Revenue Forecast, 2011-2023
Table 4.16 Russian Submarket: Revenue Forecast, 2011-2023
Table 4.17 Indian Submarket: Revenue Forecast, 2011-2023
Table 4.18 Chinese Submarket: Revenue Forecast, 2011-2023
Table 5.1 Pharmaceutical Contract Sales Market by Company, 2011
Table 5.2 inVentiv Health: Contract Sales Subsidiaries, 2012
Table 5.3 inVentiv Health: Revenue by Division, Q2 2010-2011
Table 5.4 United Drug: Contract Sales Revenue, 2008-2011
Table 5.5 United Drug: Contract Sales Revenue by Country, 2011
Table 5.6 United Drug: Contract Sales Revenue, H1 2011-2012
Table 5.7 PDI: Revenue by Client, 2010-2011
Table 5.8 PDI: Revenue by Division, 2009-2011
Table 5.9 PDI: Revenue by Division, H1 2011-2012
Table 5.10 CMIC: Contract Sales Revenue, 2008-2011
Table 5.11 Outsourced Sales Reps in Japan, 2010-2011
Table 5.12 French Contract Sales Market Leaders, 1998
Table 5.13 Sofip: Revenue, 2010-2011
Table 6.1 Pharmaceutical Contract Sales Market: Strengths and Weaknesses, 2011-2012
Table 6.2 Pharmaceutical Contract Sales Market: Opportunities and Threats, 2013-2023
Table 6.3 Pharmaceutical Contract Sales Market: STEP Analysis, 2013-2023
Table 6.4 Selected Tablet PCs Available to the Pharmaceutical Industry, 2012
Table 6.5 Big Pharma's Response to the iPad, 2010-2012
Table 6.6 Leading Suppliers of CRM Platforms, 2012
Table 6.7 Veeva Systems: New CRM Customers, 2011-2012
Table 9.1 Pharmaceutical Contract Sales Market: Revenues by Sector, 2011, 2017 and 2023
Table 9.2 Contract Non-Personal Promotion Services Submarket: Revenues by Subsector, 2011, 2017 and 2023
Table 9.3 Pharmaceutical Contract Sales Market: Revenues by Region, 2011, 2017 and 2023

List Of Figures

LIST OF FIGURES

Figure 2.1 Patent Expiries: Revenue at Risk for Big Pharma, 2012-2015
Figure 2.2 Big Pharma Sales Rep Cuts, 2011-2012
Figure 2.3 Selected Tasks Outsourced in the Pharmaceutical Industry, 2012
Figure 2.4 Selected Services Offered by CSOs, 2012
Figure 3.1 Pharmaceutical Contract Sales Market, 2009-2011
Figure 3.2 Pharmaceutical Contract Sales Market by Sector, 2011
Figure 3.3 Pharmaceutical Contract Sales Market by Sector, 2010-2011
Figure 3.4 PDI: Sales Reps Employed, 2005-2011
Figure 3.5 Pharmaceutical Contract Sales Market: Overall Market Forecast, 2011-2023
Figure 3.6 Pharmaceutical Contract Sales: Market Shares by Sector, 2017
Figure 3.7 Pharmaceutical Contract Sales: Market Shares by Sector, 2023
Figure 3.8 Personal Promotion Services Submarket: Revenue Forecast, 2011-2023
Figure 3.9 Non-Personal Promotion Services Submarket by Sector, 2011
Figure 3.10 Non-Personal Promotion Services Submarket: Revenue Forecast 2011-2023
Figure 3.11 Non-Personal Promotion Services: Submarket Shares by Sector, 2017
Figure 3.12 Non-Personal Promotion Services: Submarket Shares by Sector, 2023
Figure 3.13 Teledetailing Services Submarket: Revenue Forecast, 2011-2023
Figure 3.14 eDetailing Services Submarket: Revenue Forecast, 2011-2023
Figure 3.15 Medical Education Services Submarket: Revenue Forecast, 2011-2023
Figure 4.1 Pharmaceutical Contract Sales Market by Country, 2011
Figure 4.2 Proportion of Sales Reps Outsourced in Developed Markets, 2012
Figure 4.3 Pharmaceutical Contract Sales: Market Shares by Country, 2017
Figure 4.4 Pharmaceutical Contract Sales: Market Shares by Country, 2023
Figure 4.5 US Contract Sales Submarket: Revenue, 1995-2011
Figure 4.6 US Submarket: Revenue Forecast, 2011-2023
Figure 4.7 Pharmaceutical Contract Sales: European Market by Leading Country, 2011
Figure 4.8 European Submarket: Revenue Forecast, 2011-2023
Figure 4.9 UK Submarket: Revenue Forecast, 2011-2023
Figure 4.10 German Submarket: Revenue Forecast, 2011-2023
Figure 4.11 French Submarket: Revenue Forecast, 2011-2023
Figure 4.12 Italian Submarket: Revenue Forecast, 2011-2023
Figure 4.13 Spanish Submarket: Revenue Forecast, 2011-2023
Figure 4.14 Japanese Submarket: Revenue Forecast, 2011-2023
Figure 4.15 Brazilian Submarket: Revenue Forecast, 2011-2023
Figure 4.16 Russian Submarket: Revenue Forecast, 2011-2023
Figure 4.17 Indian Submarket: Revenue Forecast, 2011-2023
Figure 4.18 Chinese Submarket: Revenue Forecast, 2011-2023
Figure 5.1 Pharmaceutical Contract Sales Market by Company, 2011
Figure 5.2 inVentiv Health: Revenue by Division, Q2 2010-2011
Figure 5.3 Quintiles: National and Regional Market Entries, 1980-2012
Figure 5.4 United Drug: Contract Sales Revenue, 2008-2011
Figure 5.5 United Drug: Contract Sales Revenue by Country, 2011
Figure 5.6 United Drug: Contract Sales Revenue, H1 2011-2012
Figure 5.7 PDI: Revenue by Client, 2011
Figure 5.8 PDI: Revenue by Division, 2009-2011
Figure 5.9 PDI: Revenue by Division, H1 2011-2012
Figure 5.10 CMIC: Contract Sales Revenue, 2008-2011
Figure 5.11 Outsourced Sales Reps in Japan, 2010-2011
Figure 5.12 Sofip: Revenue, 2010-2011
Figure 6.1 Expanded Access to Healthcare in Developed and Emerging Markets, 2006-2011
Figure 9.1 Pharmaceutical Contract Sales Market: Revenues by Sector, 2011, 2017 and 2023
Figure 9.2 Contract Non-Personal Promotion Services Submarket: Revenues by Subsector, 2011, 2017 and 2023
Figure 9.3 Pharmaceutical Contract Sales Market: Revenues by Region, 2011, 2017 and 2023

COMPANIES LISTED

360 Vantage
Abbott Laboratories
Across Health
Actelion Pharmaceuticals
Agência Nacional de Vigilância Sanitária (ANVISA)
Akcess
Akrikhin
Allergan
Alliance Healthcare (part of United Drug)
Almirall
Apple
Ashfield Healthcare Ireland (part of United Drug)
Ashfield Healthcare (part of United Drug)
Ashfield In2Focus (part of United Drug)
Ashfield KK (part of United Drug)
Association of the British Pharmaceutical Industry (ABPI)
Astellas Pharma
AstraZeneca
Biogaran
Blue Diesel (part of inVentiv Health)
Boehringer Ingelheim
Ministério da Saúde [Brazil]
Business Edge Solutions and Training (BEST)
Cegedim Strategic Data
Celesio
Centers of Medicare and Medicaid Services (CMS) [US]
Chinese Ministry of Health
Cider Sante (part of Pharmexx)
CMIC
CMIC MPSS Co (part of CMIC)
CMR Institute [US]
Congressional Budget Office (CBO) [US]
Consumer Advisory Group [UK]
Corcept Therapeutics
Daiichi Sankyo
Dayarn Pharma
Delcath Systems
Depomed
Drug Safety Alliance (DSA, part of United Drug)
Eisai
Eli Lilly
European Commission (EC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Evolve Selection
Federation of Medical Representatives Association of India (FMRAI)
Ferring Pharmaceuticals
Food and Drug Administration (FDA) [US]
Genentech (part of Roche)
Go! Healthcare Marketing
Grey Healthcare Group
Group DCA (part of PDI)
Grünenthal
GSK
Health Kare Pharma International (HKPI)
Human Genome Sciences (part of GSK)
IMS Health
Informed Medical Communications
Innovex (part of Quintiles)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG) [Germany]
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Interpace BioPharma (part of PDI)
inVentiv Health
inVentiv Health Korea (part of inVentiv Health)
inVentiv Health Selling Solutions (part of inVentiv Health)
inVentiv Japan (part of inVentiv Health)
inVentiv Recruitment Services (part of inVentiv Health)
inVentiv Therapeutics Institute (part of inVentiv Health)
Invida
Iroko Cardio International
Japan Contract Sales Organisation Association (JCSOA)
Japan Pharmaceutical Manufacturers Association (JPMA)
Kadrige
Les enterprises du médicament (LEEM) [France]
Leo Pharma
LG
Lupin Pharmaceuticals
Marvecs
MDS Co (part of CMIC)
MELA Sciences
Menarini Group
Merck & Co.
Merqurio Group
Merqurio Pharma
Ministerio de Sanidad, Servicios Sociales e Igualdad [Spain]
Motorola
MySTRO (part of inVentiv Health)
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
NATIVE
NetworksMD/Pharmalink (part of Zuellig Pharma)
Neurocrine Biosciences
Novartis
Nycomed
OnCall
Oracle
Organisation of Pharmaceutical Producers of India (OPPI)
PDI
PDI Voice (part of PDI)
Pfizer
Pharco Pharmaceuticals
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmakon
Pharmartis
Pharmexx (part of United Drug)
Polpharma
Proton Pharma
Publicis Healthcare Communications Group
Publicis Touchpoint Solutions
Q.E.D. International (part of Quintiles)
Qforma
Quintiles
Ramco Import Export
Research in Motion (RIM)
Roche
Rottapharm Madaus
Samsung
Sanofi
Santarus
Scottish Medicines Consortium (SMC)
Sermo
Servier
Shalaks Pharmaceuticals (part of Invida)
Sinclair IS Pharma
Sofip
Stallergenes
StayinFront
Synopia Rx (part of United Drug)
Temas
Temasek Holdings
The Royce Consultancy (part of Quintiles)
Thomas H. Lee Partners
Touchpoint Recruiting Solutions
United Drug
Universal WorldEvents
Valeritas
VCG Bio
VCG & Associates
Veeva Systems
Vivus
WPP
Zuellig Group
Zuellig Pharma